title: The effects of antidepressant treatment on serum cytokines and nutritional status in hemodialysis patients.
abstract: The aim of this study was to investigate the effects of antidepressant treatment on serum cytokines and nutritional status in hemodialysis patients. Twenty-eight hemodialysis patients with a depressed mood were given 20 mg of fluoxetine for 8 weeks. The degree of depressive symptoms, the serum levels of interleukin-1beta, interleukin-2, interleukin-6, tumor necrosis factor-alpha, c-reactive protein, and markers of nutritional status were assessed at baseline and after treatment. The outcome was assessed in terms of response to treatment (>50% reduction in the score of the Hamilton depression rating scale). Antidepressant treatment decreased the serum level of interleukin-beta1 in both response and nonresponse groups, and increased the serum level of interleukin-6 only in the response group. At baseline, the level of interleukin-6 in the response group was lower than in the nonresponse group. Antidepressant treatment also increased fat distribution significantly in the response group which might have slightly improved the nutritional status. This study suggests that antidepressant treatment improve depressive symptoms and may affect immunological functions and nutritional status in chronic hemodialysis patients with depression.
authors.affiliation: Department of Psychiatry, College of Medicine, Hallym University, Chunchon, Korea.
authors.forename: Sang-Kyu
authors.initials: SK
authors.lastname: Lee
authors.forename: Hong-Seock
authors.initials: HS
authors.lastname: Lee
authors.forename: Tae-Byeong
authors.initials: TB
authors.lastname: Lee
authors.forename: Do-Hoon
authors.initials: DH
authors.lastname: Kim
authors.forename: Ja-Ryong
authors.initials: JR
authors.lastname: Koo
authors.forename: Yong-Ku
authors.initials: YK
authors.lastname: Kim
authors.forename: Bong-Ki
authors.initials: BK
authors.lastname: Son
mesh_terms: D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000494:pharmacology*; D002097:C-Reactive Protein / Q000096:biosynthesis; D016207:Cytokines / Q000097:blood*; D003863:Depression / Q000188:drug therapy*; D017097:Electric Impedance; D005260:Female; D005473:Fluoxetine / Q000494:pharmacology*; D006801:Humans; D007375:Interleukin-1 / Q000097:blood; D007376:Interleukin-2 / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D008875:Middle Aged; D009747:Nutritional Physiological Phenomena; D006435:Renal Dialysis / Q000379:methods*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
chemical_list: D018687:Antidepressive Agents, Second-Generation; D016207:Cytokines; D007375:Interleukin-1; D007376:Interleukin-2; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D005473:Fluoxetine; D002097:C-Reactive Protein